A dog model of stable mixed hematopoietic chimerism was established in which leukocyte-antigen-identical littermates receive nonmyeloablative total body irradiation before hematopoietic cell transplantation and postgrafting immunosuppression with mycophenolate mofetil and cyclosporine. Unmodified donor lymphocyte infusion (DLI) into stable mixed chimeras failed to increase donor chimerism, while DLI from donors sensitized to recipient minor-histocompatibility antigens promptly converted all recipients to complete donor chimerism. This established a model for studying approaches to enhance the graftversus-host (GVH)-effect, a potential surrogate for graftversus-leukemia activity. We asked if interleukin-2 (IL-2) given after unmodified DLI could result in reliable conversion to complete donor chimerism. IL-2, 4 Â 10 5 IU/kg/day, was administered to six mixed chimeric dogs for 14 days. Four dogs received unmodified DLI with IL-2. At 20-40 weeks after DLI, all dogs remained mixed chimeras. For the two recipients of IL-2 only, mixed chimerism also remained unchanged. These results show that IL-2 given with DLI after nonmyeloablative transplantation in dogs is not effective in reliably converting mixed to complete donor chimerism.
nonmyeloablative hematopoietic stem cell transplantation; graft-versus-host effect Long-term stable mixed hematopoietic chimerism has been established following nonmyeloablative 2 Gy total body irradiation (TBI) prior to transplantation of dog leukocyte antigen (DLA)-identical littermate marrow followed by combined postgrafting immunosuppression with mycophenolate mofetil and cyclosporine for 4 and 5 weeks, respectively. 1 Results of clinical trials have shown that mixed donor-host chimerism can be successfully established in humans with the same regimen developed in the dog model with substantially decreased toxicity compared to myeloablative conditioning. 2 For patients with hematologic malignancies who do not spontaneously convert to all donor chimerism, we hypothesized that donor lymphocyte infusion (DLI) could promote conversion to complete donor chimerism. DLI has been successfully given to patients after nonmyeloablative conditioning to convert mixed to complete donor chimerism. 3, 4 The setting of mixed chimerism could permit residual host-antigen-presenting cells to prime a graft-versus-host (GVH) response. 5 We previously reported that conversion from mixed to complete donor chimerism in long-term stable mixed chimeric dogs required DLI sensitized to recipient minor histocompatibility antigens (mHA), while unmodified DLI did not change the degree of donor chimerism. 6 We hypothesized that suppressor cells actively maintained stable mixed chimerism and donor-host tolerance, thus preventing unmodified DLI from exerting a GVH effect. Sensitization to mHA was accomplished by placing skin grafts from the mixed chimeras onto the respective marrow donors. Sensitization to recipient mHA enhanced the GVH effect of DLI, yet only two of the eight dogs studied developed graft-versus-host disease (GVHD). These observations established the enhanced GVH effect of mHA-sensitized DLI as a potential model for graftversus-leukemia (GVL) activity.
The largest clinical experience with DLI has been for treatment of chronic myeloid leukemia relapse after conventional allogeneic marrow transplantation.
7-9 DLI has not been as effective for treatment of other acute leukemias. 10 Interleukin-2 (IL-2) given after DLI has been reported to enhance the GVL-effect of DLI in murine models and in humans. [11] [12] [13] Hence, we asked if IL-2 given after unmodified DLI could activate donor T cells to convert mixed to complete donor chimerism in a canine model of nonmyeloablative hematopoietic cell transplantation.
Materials and methods

Experimental animals
Litters of random-bred dogs weighing 8. 8-14.0 kg and 7-11 months of age were raised at the Fred Hutchinson Cancer Research Center or obtained from commercial United States Department of Agriculture-licensed kennels. 14 The Institutional Animal Care and Use Committee approved the research protocol. Research was performed as per the principles in the Guide for Laboratory Animal Facilities and Care (National Academy of Sciences, National Research Council). Kennels are certified by the American Association for Accreditation of Laboratory Animal Care. DLA-identical littermate donor/recipient pairs were chosen on the basis of identity for highly polymorphic major histocompatibility complex class I and class II microsatellite markers. 15 Specific DLA-DRB1 allelic identity was determined by direct sequencing. 16 
Transplantation
The six stable mixed chimeras in this study were obtained from experiments using slightly different conditioning doses of TBI and either bone marrow and/or recombinant canine granulocyte-colony stimulating factor (G-CSF)-mobilized peripheral blood mononuclear cells (G-PBMC). 17 Cryopreserved marrow or freshly harvested donor marrow containing 2.5-4.2 Â 10 8 cells/kg was infused intravenously within 4 h of TBI.
14 G-PBMC doses ranged from 7.0-10.0 Â 10 9 cells/kg and were infused with marrow. Dog E606 received CTLA4Ig, 1 Gy TBI and marrow. 18 Dogs E688, E692 and E710 received 1 Gy TBI followed by cryopreserved marrow and G-PBMC. 19 Dogs E713 and E717 received 2 Gy TBI and marrow; dog E717 also received G-PBMC. 1, 19 TBI was delivered at 0.07 Gy/min from two opposing 60 Co sources 20 or a high energy linear accelerator (Varian CLINAC 4, Palo Alto, CA).
Post-transplant immunosuppression
All marrow recipients were given cyclosporine, 15 mg/kg twice daily orally, from days À1 to 35. Dog E606 also received mycophenolate mofetil, 10 mg/kg twice daily subcutaneously, from days 0 to 27.
18
Assessment of engraftment and chimerism Donor marrow engraftment was assessed by determination of donor cells in the marrow and peripheral blood granulocyte (G) and mononuclear cell (PBMC) populations using polymorphic microsatellite markers in a polymerase chain reaction-based assay. 21 The percent donor chimerism was assessed by phosphorimage analysis (Molecular Dynamics, Sunnyvale, CA, USA).
1 Blood for chimerism analyses was obtained weekly and fractionated by FicollHypaque gradient centrifugation. CD3 + cells were isolated by fluorescence-activated cell sorting (Vantage, Becton Dickinson, San Jose, CA, USA) of PBMC stained with FITC-conjugated anti-CD3e monoclonal antibody CA17.6F9 (provided by Dr Peter F. Moore, University of California, Davis, CA, USA). 6 Granulocytes were isolated from the sedimented erythrocyte fraction, hemolyzed, and were confirmed to be 495% positive by staining with FITC-conjugated DM5, a monoclonal antibody specific for the mature myeloid lineage restricted canine antigen gp19, 21 and 23 DM5 . 22 Controls with known ratios of donor : recipient DNA were run to standardize the assay.
Donor lymphocyte infusion
Four dogs (E688, E692, E710, E713) received DLI from their respective DLA-identical hematopoietic stem cell donors on days 212, 211, 204 and 287, respectively, after transplant. Infused CD3+ cell doses were 1.3, 1.0, 0.9 and 2.5 Â 10 8 /kg, respectively. DLIs were obtained using a Cobe-Spectra apheresis device and were given intravenously to recipients on the day of collection. 6 All recipients had been off of all immunosuppression for at least 169 days prior to IL-27DLI.
Il-2 administration
IL-2 (Chiron, Emeryville, CA, USA), 2 Â 10 5 IU/kg subcutaneously twice daily, was administered to six mixed chimeric recipients for 14 days. The IL-2 dose given was based on prior dog studies with correction for the revised IL-2 units for the clinical grade product. Human IL-2 was previously documented to cross-react with canine T cells. [23] [24] [25] Dogs E606 and E717 received IL-2 only. The four DLI recipients received the first dose of IL-2 2 h before DLI to ensure that therapeutic serum levels of IL-2 would be present upon infusion of lymphocytes. Complete blood counts with differentials were obtained daily during IL-2 administration, then weekly. Using the FITC-conjugated monoclonal antibodies CA17.6F9, CA13.1E4 and CA9.JD3, specific for canine CD3e, CD4 and CD8, respectively, the percentage and absolute number of peripheral blood T-cell subsets was measured weekly in all six recipient dogs for a total of 7 weeks, beginning immediately before IL-27DLI.
Statistical analysis
Confidence intervals were used to describe the statistical significance of the study outcome. At the study outset, we hypothesized that virtually all the dogs treated with DLI and IL-2 would convert to complete donor chimerism.
Results
Six stable mixed chimeric dogs were treated with IL-2 for 14 days. Two control dogs (E606 and E717) did not receive DLI, while four dogs received unmodified DLI and IL-2. As shown in Figure 1 , IL-2 administration into mixed chimeras resulted in reversible leukocytosis, lymphocytosis and eosinophilia. Corresponding with the transient increase in white blood cell count (WBC), absolute lymphocyte count (lymph) and eosinophils (EOS), there was an increase in the absolute number of CD3+,CD4+ and CD8+ T-cells/L assessed by flow cytometry without a discernibly significant change in the relative proportions of T-cell subsets (data not shown). No additional functional T-cell studies were performed. The only other hematologic effect of IL-2 observed was in dog E688 that developed significant thrombocytopenia with a platelet count nadir of 33 Â 10 9 /l 6 days after the initiation of IL-2 treatment. The platelet count recovered to normal (4200 Â 10 9 /l) within 1 week after discontinuation of IL-2. Thrombocytopenia (o100 Â 10 9 /l) was not seen in the other five IL-2 recipients.
There were no apparent clinical differences between DLI recipients and dogs not given DLI. All six dogs developed progressive lethargy, anorexia, fever, moderate diarrhea and skin erythema that approached dose-limiting toxicities during IL-2 administration. There was no significant weight loss noted. Within 2 days of discontinuation of IL-2, all symptoms had resolved. In the previously reported series of unmodified and mHA-sensitized DLI given to eight mixed chimeras, none of these above findings were observed. 6 This indicated that all observed side effects were because of IL-2 administration.
Before and after IL-27DLI, the chimerism status of peripheral blood cells was assessed. Figure 2 shows reversible minor decreases in donor chimerism in some dogs. However, after 20-40 weeks of follow-up, there was no evidence of a substantial change in donor chimerism, and none of the dogs achieved complete donor chimerism. Of note, there was a decreasing donor chimerism in dog E688 prior to IL-2+DLI. After IL-2+DLI, the percent donor chimerism increased, predominantly in the myeloid compartment, and returned to the week À20 levels. There were no apparent differences between recipients of DLI and dogs not given DLI. In the previous study of mHAsensitized DLI, conversion to complete donor chimerism occurred in eight of eight dogs within 2-12 weeks of lymphocyte infusions despite lower CD3+ cell doses (mean, 7.8 Â 10 7 CD3 + /kg) than were used in the current study. 6 At the outset of the current study, we defined success of IL-2+DLI intervention as conversion to complete (100%) donor chimerism in virtually all dogs. This study showed 0 success out of four dogs. As such, the 95% confidence internal was 0-60%, and the 99% confidence interval is 0-73%, indicating that the true likelihood that IL-2+DLI could convert mixed chimeras to complete donor chimerism was less than 60 and 73%, respectively. These results suggest that studying additional dogs would not be appropriate if our goal was to reliably achieve conversion to complete donor chimerism.
Discussion
The results of the current study show that IL-27unmodi-fied DLI given to stable mixed hematopoietic chimeras did not result in conversion to complete donor chimerism. IL-2 doses used in this study had biologic activity, since all clinical evidence of toxicity promptly resolved after IL-2 was stopped. There was no evidence of a reliable GVHenhancing effect of IL-2 as overall hematopoietic chimerism remained unchanged. However, one dog, E688, showed reversal of declining donor myeloid chimerism after IL-2+DLI. The lack of conversion to complete donor chimerism in the animals studied made it very unlikely that studying additional animals with the doses of IL-2 and DLI used would result in reliable conversion to 100% donor chimerism. The toxicity of IL-2 in the allogeneic hematopoietic stem cell transplant setting has been, at least in part, attributed to a GVH-enhancing effect. 13, 26, 27 However, the current study suggests the observed clinical toxicity of IL-2 may not be related to a GVH-effect. Nonetheless, it is possible that another method of administration of IL-2 in mixed chimeras could serve to enhance a GVH-effect. To date, only sensitized DLI was able to break tolerance and consistently convert mixed to complete donor chimerism in this model. Reasons for why IL-2 was ineffective in promoting unmodified DLI to convert mixed to complete donor chimerism include the following potential explanations. First, in unsensitized DLI, the precursor frequency of donor T cells recognizing mismatched host minor histocompatibility antigens is so low that even after activation by IL-2, they are insufficient to convert to 100% donor chimerism. Second, in vivo administration of IL-2 activates residual host allo-reactive T cells which negate the effect of DLI. Third, there is no effect of systemically administered IL-2 in enhancing proliferation and cytotoxicity of donorderived, mHA-specific T and NK cells in vivo because of pharmacokinetic or biologic regulatory factors. To address these possibilities, additional experiments to investigate cytotoxic T lymphocyte precursor (CTLp) frequencies against host PBMC before and after IL-27DLI may have been informative. Unfortunately, CTLp assays are not established in the DLA-identical model.
The current study of IL-27DLI in mixed chimeras is directly comparable to our previous study of sensitized vs unmodified DLI in mixed chimeras even though a variety of nonmyeloablative preparative regimens were used for generating mixed hematopoietic chimerism. First, recipients were treated with 1 or 2 Gy TBI and received marrow or G-PBMC as did the mixed chimeras studied in our previous report of sensitized DLI. Second, all dogs in this study were long-term, stable mixed chimeras in all hematopoietic lineages. Finally, we have observed no biologic difference in mixed chimeras generated with a variety of nonmyeloablative regimens, further emphasizing the robust nature of stable mixed chimerism in this large animal model. 1, 18, 19, 28, 29 IL-2 may potentially enhance the GVL-effect after allogeneic hematopoietic cell transplantation, although supporting clinical evidence is limited. 13, 26 IL-2 stimulates the proliferation of antigen-specific or activated T cells and B cells, induces expansion of NK cells, and induces the secretion of other lymphokines, such as interferon-g, GM-CSF, and tumor necrosis factor, and augments the cytolytic function of T cells and NK cells. [30] [31] [32] [33] IL-2 was given after HLA-matched sibling bone marrow transplantation for patients with acute leukemia; however, the risk of toxicity has limited the enthusiasm for this treatment approach. 26, 27 Slavin et al 13 reported on the feasibility and potential effectiveness of IL-2 plus DLI for treatment of leukemia relapse after allogeneic transplantation by preincubation of donor lymphocytes with IL-2 in vitro followed by in vivo IL-2 administration. 13 In summary, a biologically active dose of subcutaneous IL-2 administered to stable mixed canine chimeras for 14 days failed to convert dogs from mixed to complete donor chimerism. The results from this preclinical model suggest that the addition of IL-2 to DLI is unlikely to reliably convert stable mixed to all-donor chimerism in patients following nonmyeloablative conditioning and hematopoietic cell transplantation.
